Deals: Page 3


  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    After summer slump, biotech M&A has a good week

    There have been few bigger-ticket acquisitions recently. But a string of deals announced in early October, including the purchase of Orchard Therapeutics, may affirm the forecasts of analysts who expect M&A to tick up.

    By Oct. 10, 2023
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers to buy KRAS cancer drug developer Mirati for $4.8B

    Mirati investors could also receive another $1 billion should an experimental cancer drug the biotech is developing make it to U.S. regulators’ desks.

    By Oct. 8, 2023
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • Large letters spelling Amgen are seen next to a stone wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Amgen completes $28B Horizon buyout that was challenged by FTC

    Regulators’ holdup of the deal had stoked investor fears of greater scrutiny on M&A. In the end, Amgen agreed to requirements meant to guard against product “bundling.”

    By Oct. 6, 2023
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie acquires Parkinson’s drug in latest biotech buyout

    The company exercised an option to buy Mitokinin, a private, Pfizer-backed drugmaker built on work by scientific co-founders Nicholas Hertz and Kevan Shokat.

    By Oct. 5, 2023
  • Intellia Therapeutics
    Image attribution tooltip
    Permission granted by Intellia Therapeutics
    Image attribution tooltip

    Regeneron, Intellia target neurological diseases in expanded gene editing deal

    The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

    By Oct. 3, 2023
  • Prostate cancer cells, 3D illustration. Prostate cancer awareness image
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout

    Point Biopharma is one of the most advanced in a group of emerging biotechs working on radioligand therapies for cancer.

    By Oct. 3, 2023
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris sells off consumer, women’s health drugs in asset sales

    The divestments will bring in more than $3 billion as the company works to reduce its debt and plan for future business development.

    By Oct. 2, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche bets on Ionis RNA medicines with neuroscience deal

    The Swiss drugmaker is restocking its pipeline by buying into preclinical Ionis medicines for Alzheimer’s and Huntington’s diseases.

    By Sept. 27, 2023
  • People walk past a building in New York City
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Intercept, after biotech rollercoaster ride, agrees to buyout by Alfasigma

    Once valued at more than $7 billion, the liver drug company couldn’t secure a long-sought FDA approval in NASH and last month said it would abandon that research.

    By Sept. 26, 2023
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Image attribution tooltip

    Roche’s Genentech bets on radiopharmaceuticals in partnership with PeptiDream

    The new deal expands on a yearslong partnership between the two drug developers to advance targeted radioisotopes for certain cancers.

    By Sept. 20, 2023
  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive
    Image attribution tooltip

    Novartis cancels Beigene partnership as cancer drug gains EU approval

    The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.

    By Sept. 19, 2023
  • Header image for "How CFOs Can Raise Financing During a Downturn"
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Bausch + Lomb seeks funding for eye drug acquisition from Novartis

    Fitch Ratings called the deal to buy the Xiidra treatment “strategically sound” even as the company’s plan for funding the deal would increase its leverage.

    By Nick Paul Taylor • Sept. 12, 2023
  • A micrograph showing triglyceride fat accumulated inside liver cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Kriya, flush with funding, buys a gene therapy for NASH

    Fresh off a Series C fundraise, Kriya has acquired the privately held Tramotane Therapeutics and its preclinical candidate for the widely prevalent liver disease.

    By Kristin Jensen • Sept. 7, 2023
  • peanuts
    Image attribution tooltip
    Christopher Doering/BioPharma Dive
    Image attribution tooltip

    Nestle gives up on peanut allergy treatment after sluggish sales

    The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

    By Sept. 5, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    FTC allows Amgen’s $28B deal for Horizon to go through, with conditions

    The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.

    By Sept. 1, 2023
  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo, continuing deal streak, buys another obesity drug startup

    The acquisition of Embark Biotech, which Novo helped found, gives the company another prospect to add to its arsenal of weight-loss medicines.

    By Aug. 30, 2023
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon

    Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.

    By Aug. 28, 2023
  • Image of a person wearing lab goggles and pouring a liquid out of a beaker.
    Image attribution tooltip
    Courtesy of Abcam
    Image attribution tooltip

    Danaher to buy antibody supplier Abcam for $5.7B

    The acquisition gives Danaher ownership of a producer of research tools, such as antibodies and reagents, that are used in drug discovery experiments.

    By Elise Reuter • Aug. 28, 2023
  • A stylized illustration of the human urinary system with the bladder highlighted.
    Image attribution tooltip
    magicmine via Getty Images
    Image attribution tooltip

    Royalty Pharma buys into Ferring’s cancer treatment in first gene therapy deal

    The deal, worth up to $500 million, is a bet by the drug rights dealmaker on the uncertain commercial prospects of Ferring's gene therapy Adstiladrin.

    By Aug. 24, 2023
  • Securities and Exchange Commission, SEC, Building in Washington DC
    Image attribution tooltip
    qingwa via Getty Images
    Image attribution tooltip

    Illumina faces SEC probe over Grail acquisition

    The regulator has asked for documents tied to the 2021 deal as well as to the conduct and compensation of Illumina and Grail management.

    By Susan Kelly • Aug. 14, 2023
  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo adds another obesity drug in $1B deal for startup Inversago

    The acquisition follows a similar-sized, obesity-focused buyout by Eli Lilly last month and hands Novo a weight-loss medicine already in mid-stage testing. 

    By Kristin Jensen • Aug. 10, 2023
  • Regeneron ups genetic medicine investment with Decibel buyout

    Third Rock-founded Decibel, which has shed much of its value since a 2021 IPO, expected to run out of money within a year.

    By Aug. 9, 2023
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Ikena acquires cancer startup Pionyr after Gilead passes on buyout

    The all-stock deal comes months after Gilead waived an option to buy Pionyr, and gives Ikena some needed breathing room in a tough market.

    By Aug. 7, 2023
  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive
    Image attribution tooltip

    Agios turns to Alnylam for help with rare disease push

    The biotech is acquiring rights to an RNA interference medicine Alnylam invented for a rare blood disorder, continuing a corporate makeover that began in 2020. 

    By Kristin Jensen • Aug. 3, 2023
  • TG shares tumble following licensing deal for MS drug

    Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

    By Aug. 1, 2023